Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)

Late-breaking presentation at acg 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose dupixent in these children

REGN Ratings Summary

REGN Quant Ranking